| 曲妥珠单抗对30例Her2阳性中国乳腺癌患者术后辅助治疗安全性的初步观察 |
| |
| 引用本文： | 周宁宁,滕小玉,刘冬耕,许然,管忠震. 曲妥珠单抗对30例Her2阳性中国乳腺癌患者术后辅助治疗安全性的初步观察[J]. 癌症, 2008, 27(12): 1307-1309 |
| |
| 作者姓名： | 周宁宁 滕小玉 刘冬耕 许然 管忠震 |
| |
| 作者单位： | 华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060;华南肿瘤学国家重点实验室,广东,广州,510060;中山大学肿瘤防治中心内科,广东,广州,510060 |
| |
| 摘 要： | 背景与目的:国际多中心研究已经证实,曲妥珠单抗对Her2阳性的晚期乳腺癌和早期乳腺癌术后辅助治疗均有良好的疗效.本文中我们主要探讨Her2阳性中国乳腺癌患者术后完成辅助治疗后应用曲妥珠单抗的安全性.方法:早期乳腺癌患者术后完成辅助化疗和/或放疗后接受3周一次的曲妥珠单抗治疗,首次以负荷剂量8 mg/kg给药,然后每3周给予6 mg/kg静脉滴注,至少接受治疗4疗程,最长35疗程,观察其不良反应.特别是对心脏功能的影响.结果:共30例Her2阳性的乳腺癌患者术后接受曲妥珠单抗治疗,中位治疗疗程数是18个(4～35个),有2例在第一次用药时出现寒战和发热.18例患者治疗后LVEF下降,其中9例下降超过10%.24例治疗过程中曾出现轻度ST-T波改变,但未出现心力衰竭.结论:曲妥珠单抗对Her2阳性中国乳腺癌患者心脏功能有一定影响,应在治疗中注意监测观察,但总体安全性良好.
|
| 关 键 词： | 乳腺肿瘤/联合治疗 Her-2阳性 曲妥珠单抗/治疗应用 安全性 |
Primary Safety Analysis of Trastuzumab after Adjuvant Chemotherapy in 30 Chinese Her2-positive Early Breast Cancer Patients |
| |
| ZHOU Ning-Ning,,TENG Xiao-Yu,LIU Dong-Geng,XU Ran,GUAN Zhong-Zhen,. State Key laboratory of Oncology in South China,Guangzhou,Gu,ong,,P.R. China. Primary Safety Analysis of Trastuzumab after Adjuvant Chemotherapy in 30 Chinese Her2-positive Early Breast Cancer Patients[J]. Chinese journal of cancer, 2008, 27(12): 1307-1309 |
| |
| Authors: | ZHOU Ning-Ning TENG Xiao-Yu LIU Dong-Geng XU Ran GUAN Zhong-Zhen . State Key laboratory of Oncology in South China Guangzhou Gu ong P.R. China |
| |
| Affiliation: | ZHOU Ning-Ning1,2,TENG Xiao-Yu1,LIU Dong-Geng1,XU Ran1,GUAN Zhong-Zhen1,21. State Key laboratory of Oncology in South China,Guangzhou,Gu,ong,510060,P.R. China 2. Department of Medical Oncology,Cancer Center,Sun Yat-sen University,Guangdong,P. R. China |
| |
| Abstract: | BACKGROUND & OBJECTIVE: It has been proved that trastuzumab has clinical activity in early and advanced breast cancer with Her2-overexpression. This study was to analyze the safety of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients. METHODS: Trastuzumab was administrated after adjuvant chemotherapy every 21 days . The initial dose was 8 mg / kg , and the subsequent dose was 6 mg / kg, for four to 35 cycles (medium 18 cycles). The side effects of these patient... |
| |
| Keywords: | Breast neoplasm / combined therapy Her2 positive Trastuzumab Safety |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
